Suppr超能文献

过氧化物酶体增殖物激活受体β/γ介导了一种由[具体物质1]和[具体物质2]组成的合生元制剂对自发性高血压大鼠的降压活性。

PPAR beta/gamma mediates the antihypertensive activity of a synbiotic preparation of and in spontaneous hypertensive rats.

作者信息

Huang Ying, Wang Fang, Gong Wei, Chen Yufeng

机构信息

Department of Cardiovascular, Liaoning Jin Qiu Hospital, No.317 Xiaonan Street, Shenhe District, Shenyang, Liaoning Province, 110016, China.

Department of Nursing, General Hospital of Northern Theater Command, No.83 Wenhua Road, Shenhe District, Shenyang, Liaoning Province, 110016, China.

出版信息

Heliyon. 2024 Aug 13;10(16):e36157. doi: 10.1016/j.heliyon.2024.e36157. eCollection 2024 Aug 30.

Abstract

BACKGROUND

Hypertension is a global public health concern. A synbiotic preparation containing and has been used as adjunct therapy for hypertension. We sought to elucidate the antihypertensive activity of this preparation and explore the underlying mechanisms.

METHODS AND RESULTS

Blood pressure in rats was measured using the tail-cuff method. Colonization of the gastrointestinal tract by the two probiotics was determined by real-time quantitative polymerase chain reaction (qPCR). Mechanistic studies were performed by proteomic analyses based on liquid chromatography-mass spectrometry and STRING database and metabolomic analyses using the UHPLC-Q-TOF/MS platform and peroxisome proliferator-activated receptor (PPAR)β/γ antagonists. Although biochemical analysis of blood samples showed that the synbiotic preparation did not alter the levels of angiotensin II, aldosterone, or cortisol, it significantly lowered the systolic blood pressure in the treatment group. Moreover, the synbiotic preparation contributed to the localization of the two probiotics in the ileum and colon of the treatment group. Proteomics, immunochemistry, and real-time qPCR analyses showed that administration of the synbiotic preparation activated the PPAR signaling pathway in the ileum and significantly upregulated PPARβ and PPARγ. The antagonist studies further confirmed this finding. In addition, metabolomic analyses demonstrated that among the 27 metabolites that showed significant differences between the control and model groups, administration of the synbiotic preparation significantly upregulated lysophosphatidylethanolamine and phosphatidylcholine in the ileum of the treatment group.

CONCLUSION

The results of the study suggest that the novel synbiotic preparation reduces blood pressure by altering the composition of the intestinal microbiota, regulating PPAR signaling pathway, and activating the PPARβ and PPARγ cascade reactions in the ileum.

摘要

背景

高血压是一个全球公共卫生问题。一种含有[具体成分1]和[具体成分2]的合生元制剂已被用作高血压的辅助治疗。我们试图阐明该制剂的降压活性并探索其潜在机制。

方法与结果

采用尾套法测量大鼠血压。通过实时定量聚合酶链反应(qPCR)确定两种益生菌在胃肠道的定植情况。基于液相色谱 - 质谱联用和STRING数据库的蛋白质组学分析以及使用超高效液相色谱 - 四极杆 - 飞行时间质谱(UHPLC - Q - TOF/MS)平台和过氧化物酶体增殖物激活受体(PPAR)β/γ拮抗剂进行代谢组学分析来开展机制研究。尽管血液样本的生化分析表明合生元制剂未改变血管紧张素II、醛固酮或皮质醇的水平,但它显著降低了治疗组的收缩压。此外,合生元制剂促使两种益生菌定位于治疗组的回肠和结肠。蛋白质组学、免疫化学和实时qPCR分析表明,给予合生元制剂可激活回肠中的PPAR信号通路,并显著上调PPARβ和PPARγ。拮抗剂研究进一步证实了这一发现。此外,代谢组学分析表明,在对照组和模型组之间显示出显著差异的27种代谢物中,给予合生元制剂显著上调了治疗组回肠中的溶血磷脂酰乙醇胺和磷脂酰胆碱。

结论

研究结果表明,这种新型合生元制剂通过改变肠道微生物群的组成、调节PPAR信号通路以及激活回肠中的PPARβ和PPARγ级联反应来降低血压。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01a/11379581/a2ec73f8b772/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验